Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole. A pilot study.
In Germany, clomethiazole (CLO) and benzodiazepines are predominantly used as therapeutic agents in the treatment of the alcohol withdrawal syndrome (AWS). These agents have disadvantages such as sedation, risk of respiratory insufficiency, and cardiovascular complications as well as addictive potential. Alternatively, it could be demonstrated that both tiapride (TIA) and carbamazepine (CBZ) are efficient in the treatment of AWS with less toxicity. However, they seem to be less effective in AWS than CLO as single agents. But no systematic comparison of the combination of TIA and CBZ against an established therapeutic standard can be found in the literature. Therefore, we compared the combination of TIA and CBZ with CLO in two open exploratory studies with matched samples. Outcome parameters were heart rate, blood pressure, complications, withdrawal symptoms (CIWA-Ar scale), and general clinical state (CGI scale). A retrospective evaluation of medical records (30 TIA+CBZ, 30 CLO) was followed by an open prospective study (40 TIA+CBZ, 40 CLO). Both studies revealed similar efficacy in terms of psychopathologic and vegetative symptoms. Vegetative recovery seems to be faster with TIA+CBZ. Results of this exploratory study have to be confirmed by a controlled double-blind study with severity of AWS as an experimental factor.
Franz
M
M
Justus Liebig University School of Medicine, Centre for Psychiatry, Giessen, Germany.
Dlabal
H
H
Kunz
S
S
Ulferts
J
J
Gruppe
H
H
Gallhofer
B
B
D000328:Adult; D000430:Alcohol Withdrawal Delirium / Q000150:complications / Q000188:drug therapy*; D020270:Alcohol Withdrawal Seizures / Q000209:etiology*; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use*; D002719:Chlormethiazole / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013976:Tiapamil Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D002719:Chlormethiazole; D002220:Carbamazepine; D013976:Tiapamil Hydrochloride